Dean’s Seminar Series featuring Jonathan Schneck, MD, PhD – “Engineering artificial Antigen Presenting Cells, aAPC, for cancer immunotherapy: From bench to bedside”

Dean’s Seminar Series

Jonathan Schneck, MD, PhD
Professor, Department of Pathology
Johns Hopkins Translational Immunology, JH-TIE, Director
The Johns Hopkins Institute for Cell Engineering

Title & Abstract:

“Engineering artificial Antigen Presenting Cells, aAPC, for cancer immunotherapy: From bench to bedside”

Adoptive Cellular Therapies, ACT, are promising immunotherapeutic approaches for treatment of cancer. While clinically ACT has led to significant successes, many challenges remain that prevent ACT from becoming front line therapy.  In this presentation we will discuss the challenges associated with current approaches and show how artificial Antigen Presenting Cells, aAPC, represent an off-shelf, scalable approach to production of clinical scale and grade T cells. Thus, aAPC based approaches represent a novel innovative approach for the immunotherapy of cancer.